Vincent Miller

Title: Vincent Miller and EGFR Mutation Detection Patents.

Introduction

Vincent Miller is an inventor associated with Memorial Sloan Kettering Cancer Center in New York, New York. His patent work focuses on detecting drug-resistant mutations in the epidermal growth factor receptor (EGFR), which can help assess whether certain cancer treatments may be effective.

Latest Patents

Miller is associated with 2 patents, including work titled “Methods and Compositions for Detecting a Drug Resistant EGFR Mutant.” The invention describes polymerase chain reaction (PCR) primers, methods, and kits for identifying the EGFR T790M mutation, a change involving a substitution of threonine by methionine at position 790 of the EGFR protein.

The disclosed methods selectively detect a mutant T at the position corresponding to base 2369 of EGFR cDNA, distinguishing it from the wild-type C. The invention also describes using this detection to predict resistance to EGFR tyrosine kinase inhibitors, including gefitinib and erlotinib, in people with or suspected of having cancer.

Career Highlights

Miller’s patent contributions address a clinically relevant challenge in cancer treatment: identifying acquired resistance to targeted therapies. The described diagnostic approaches use mutation-specific detection to support assessment of treatment resistance.

Collaborations

Miller’s listed coworkers include Harold E. Varmus and William Pao. His work is associated with Memorial Sloan Kettering Cancer Center.

Conclusion

Vincent Miller’s patent work centers on detecting drug-resistant EGFR mutations and applying that information to the assessment of targeted cancer therapies.